文献速递肿瘤 PET/CT核素与放射性配体治疗

用于乳腺癌异种移植模型中ER和HER2表型分型的临床前PET双示踪剂成像方案

A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts.
PubMed 文献 · EJNMMI Res · 2020-06-26

研究在携带ER+/HER2-(MCF-7)与ER-/HER2+(JIMT-1)乳腺癌异种移植瘤的裸鼠中,序贯使用快速清除的18F-4FMFES(靶向ER)和慢速清除的89Zr-DFO-曲妥珠单抗(靶向HER2)进行双示踪剂PET成像,评估在可接受时间窗内特异识别两种表型的可行性。结果显示该方案可在从4FMFES注射至89Zr-T最终扫描的72小时内提供高对比度肿瘤图像。

要点

  • 89Zr-DFO-曲妥珠单抗在注射后48小时即可提供高对比度肿瘤图像。
  • 18F-4FMFES在MCF-7肿瘤中的摄取显著增高。
  • 双示踪剂序贯成像可在72小时内特异显示ER+/HER2-与ER-/HER2+肿瘤。

核心结论

  • 该方案可在从4FMFES注射至89Zr-T最终扫描的3天内提供表达ER或HER2肿瘤的高对比度图像,为未来包含抗体的双示踪剂组合提供了基础。

研究设计与样本

  • 雌性裸鼠皮下植入ER+/HER2-的MCF-7与ER-/HER2+的JIMT-1细胞系于对侧肩部,另建立原位植入MCF-7或JIMT-1的模型。
  • 先对JIMT-1荷瘤小鼠进行89Zr-DFO-曲妥珠单抗的药代动力学分析、系列PET成像和生物分布至注射后8天。
  • 双示踪剂方案中,第1天给予靶向ER的4FMFES并在注射后45分钟成像,随后立即注射89Zr-T,第3天或第7天成像。

主要发现

  • 89Zr-T在注射后48小时提供足够高的肿瘤摄取和低背景摄取,生成高对比度肿瘤图像。
  • 4FMFES在MCF-7肿瘤中的摄取值显著增高。
  • 89Zr-T-PET与18F-4FMFES-PET联合时,整个双示踪剂序贯成像流程从开始到结束短至72小时,可特异提供ER+/HER2- MCF-7和ER-/HER2+ JIMT-1肿瘤的高质量对比图像。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Nuclear medicine is on the constant search of precision radiopharmaceutical approaches to improve patient management. Although discordant expression of the estrogen receptor (ER) and the human epidermal growth factor receptor 2 (HER2) in breast cancer is a known dilemma for appropriate patient management, traditional tumor sampling is often difficult or impractical. While 2-deoxy-2[18F]fluoro-D-glucose (18F-FDG)-positron emission tomography (PET) is an option to detect subclinical metastases, it does not provide phenotype information. Radiolabeled antibodies are able to specifically target expressed cell surface receptors. However, their long circulating half-lives (days) require labeling with long-lived isotopes, such as 89Zr, in order to allow sufficient time for tracer clearance from the blood compartment and to accumulate adequately in target tumors and, thus, generate high-quality PET images. The aim of this study was to develop a dual-tracer PET imaging approach consisting of a fast-clearing small molecule and a slow-clearing antibody. This approach was evaluated in a model consisting of mice harboring separate breast cancer xenografts with either an ER+/HER2- or ER-/HER2+ phenotype, comparable to human metastatic disease with intertumor heterogeneity. Lastly, the aim of our study was to determine the feasibility of specifically identifying these two important phenotypes in an acceptable time window. METHODS: Female nude mice were subcutaneously implanted on opposite shoulders with the ER+/HER2- and ER-/HER2+ MCF-7 and JIMT-1 tumor cell lines, respectively. A second model was developed consisting of mice implanted orthotopically with either MCF-7 or JIMT-1 cells. Pharmacokinetic analysis, serial PET imaging, and biodistribution were first performed for [89Zr]Zr-DFO-trastuzumab (89Zr-T) up to 8 days post-injection (p.i.) in JIMT-1 bearing mice. Region-of-interest (ROI) and biodistribution-derived uptake (% injected-activity/gram of tissue [%IA/g]) values and tumor-to-background ratios were obtained. Results were compared in order to validate ROI and identify early time points that provided high contrast tumor images. For the dual-tracer approach, cohorts of tumor-bearing mice were then subjected to sequential tracer PET imaging. On day 1, mice were administered 4-fluoro-11β-methoxy-16α-[18F]-fluoroestradiol (4FMFES) which targets ER and imaged 45 min p.i. This was immediately followed by the injection of 89Zr-T. Mice were then imaged on day 3 or day 7. ROI analysis was performed, and uptake was calculated in tumors and selected healthy organs for all radiotracers. Quality of tumor targeting for all tracers was evaluated by tumor contrast visualization, tumor and normal tissue uptake, and tumor-to-background ratios. RESULTS: 89Zr-T provided sufficiently high tumor and low background uptake values that furnished high contrast tumor images by 48 h p.i. For the dual-tracer approach, 4FMFES provided tumor uptake values that were significantly increased in MCF-7 tumors. When 89Zr-T-PET was combined with 18F-4FMFES-PET, the entire dual-tracer sequential-imaging procedure provided specific high-quality contrast images of ER+/HER2- MCF-7 and ER-/HER2+ JIMT-1 tumors for 4FMFES and 89Zr-T, respectively, as short as 72 h from start to finish. CONCLUSIONS: This protocol can provide high contrast images of tumors expressing ER or HER2 within 3 days from injection of 4FMFES to final scan of 89Zr-T and, hence, provides a basis for future dual-tracer combinations that include antibodies.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Paquette M, Phoenix S, Lawson C, et al. A preclinical PET dual-tracer imaging protocol for ER and HER2 phenotyping in breast cancer xenografts. EJNMMI Res. 2020. PMID: 32592121. doi:10.1186/s13550-020-00656-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。